QIAGEN drives the development of companion diagnostics with two key appointments for the new Pharma Business Development Team
Apr 19 2010

QIAGEN drives the development of companion diagnostics with two key appointments for the new Pharma Business Development Team

Manchester, UK, 19 April 2010 QIAGEN has today announced the appointment of two high level members, Dr Pia Garguilo and Richard Watts, to the recently formed Pharma Business Development team. Following the acquisition of DxS by QIAGEN in September 2009, this new functional group has been established to oversee all new drug-diagnostic co-development programmes with pharma companies. QIAGEN has a strong track record of pharma deals with high profile drug companies such as Amgen, Bristol Myers Squibb/Imclone/Lilly, AstraZeneca, Boehringer Ingelheim and most recently Pfizer. Other collaborations and partnerships are currently in the pipeline.  

The recent creation and rapid expansion of the Pharma Business Development team is part of QIAGEN's campaign to develop personalized healthcare solutions in partnership with the pharma industry through companion diagnostic co-development programs. The acquisition of DxS by QIAGEN brings a wide range of benefits to current and future pharma partners offering international marketing and sales and distribution channels, complete molecular diagnostic solutions with platforms and supporting chemistries, and global regulatory support.

Dr. Pia Gargiulo joins as Senior Director of Pharma Business Development, and Richard Watts takes a new role as Director of Pharma Business Development. Pia and Richard join a strong team of companion diagnostic professionals including Peter Collins, VP Pharma Business Development and previously SVP Business Development at DxS who leads the team, and Dr. David Jackson, Senior Director of Pharma Business Development, former VP Business Development and Licensing at DxS. The Pharma business team has a global reach with its members based in Manchester and Crawley in the UK, and in Dallas and Chicago in the US.

Dr. Pia Gargiulo is based in Chicago and joins QIAGEN from the Medical Affairs/Oncology department of AstraZeneca LP where she was a Senior Regional Scientific Manager working with breast, lung, colorectal and prostate cancer pipelines. She has over 15 years experience in industry and academia with a strong focus in Oncology. Prior to her tenure at AstraZeneca Pia worked with Oncor, and later Vysis to support development of their respective Her2 diagnostics, and specialized in Leukemia research at the Northwestern Medical School and University of Chicago. Pia has a PhD in cytogenetics from the Northwestern Medical School, is a regional member of the American Cancer Society, I-Bio and World Business Chicago and was recently appointed to the Governor's Commission on Women's Health.

Richard Watts is the former Pharma Regional Marketing Manager at QIAGEN, a position he has held since 2006. Richard brings to the team more than 12 years commercial experience in next generation technologies for genetic analysis. Previously Richard worked at Invitrogen following the acquisition of DNA Research Innovations where he successfully aided in the company's sale in 2004. He has also held positions at Nanogen, Packard Bioscience and Bio-Rad. Richard has a BSc in Molecular Biology from Bath University, he is an associate fellow of the Royal Society of Medicine in the UK.

Peter Collins believes in the opportunities and potential that drug-diagnostic co-development programmes for pharma partners create: "It is great to be able to welcome Pia and Richard to this dynamic new team. Both bring a wealth of commercial expertise and a unique industry perspective to the table and will play a key part in further strengthening QIAGEN's position as the pharmaceutical industry's companion diagnostic partner of choice."

QIAGEN offers one of the broadest menus of molecular sample and assay technologies in the industry. The broad portfolio covers all application areas in healthcare: prevention, profiling, point of need and personalized healthcare. With QIAGEN placing a great emphasis on the personalized healthcare function and an industry-wide interest in companion diagnostic co-development increasing - QIAGEN is active in more than 15 partnerships with pharmaceutical and large biotech companies in the field of personalized healthcare - the scope of the team looks set to increase with potential further appointments to follow.

About Companion Diagnostics 

Companion Diagnostics is integral to the part of personalized healthcare which allows physicians to determine patients' potential responses to drug treatment. These diagnostic tests are developed together with drugs for particular populations. By testing for specific genetic variations related to certain biomarkers, health professionals can customize their treatments to achieve the best possible therapeutic results and avoid unnecessary treatments.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing, molecular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.


Share this page